Pharmatalkradio

To learn more about the DPHARM: Disruptive Innovations to Modernize Clinical Research conference, visit DPHARMconference.com. 

Learn more about the DPHARM: Disruptive Innovations to Modernize Clinical Research conference, visit DPHARMconference.com. 

For more information on Patients as Partners in Clinical Research, visit patientsaspartnersconference.com. 

Learn more about Patients as Partners in Clinical Research at patientsaspartnersconference.com. 

Learn more about CRAACO: Clinical Research as a Care Option, at CRAACOevent.com

Learn more about CRAACO: Clinical Research as a Care Option, at CRAACOevent.com

Learn more about CRAACO: Clinical Research as a Care Option, at CRAACOevent.com

Learn more about CRAACO: Clinical Research as a Care Option, at CRAACOevent.com

Learn more about CRAACO: Clinical Research as a Care Option, at CRAACOevent.com

In this Episode: As clinical trials become more complex, sampling schemes keep pace. That makes proper sample and inventory management so crucial.  Slope's Hope Meely and Kyle Baker shed light on the intricacies and the complexities related to clinical inventory management and sample management. Listeners can learn more about clinical inventory involved for biospecimens, the challenges experienced in executing clinical trials and how these issues can be resolved.   Speakers:  Hope Meely, Chief Clinical Officer, Slope Hope Meely is the Chief Clinical Officer at Slope, the industry-leading provider of a clinical trial execution platform for highly complex, sample-intensive clinical trials. Hope has spent the entirety of her 25-year clinical research career supporting several sponsors and CROs in leading clinical operations teams in the execution of their clinical trial programs. Most recently, she spent 3 years in a growing biotech leading operations for a robust early phase oncology pipeline.  Kyle Bake

About the Episode: For those of us who work in clinical trials, we know all too well that the majority of sites don't hit recruitment targets, resulting in costly delays and burnout from sites and patients.  Tegan Mead and Julie Mansson, both at Javara, describe how they are applying data and technology to identify the right fit and make sure that sites are set up for success, advising sponsors on making trials less burdensome for patients, and keeping physicians in the loop on trials for their patients, to make clinical trials more successful in more places, for the benefit of patients.    About the Speakers:  Tegan Mead, Executive Director of Operational Excellence, Javara Tegan Mead began her career in clinical research in 2014, working as a Clinical Operations Manager at PMG Research. She has served in various roles across the site enterprise, including operational leadership, feasibility management and operational excellence, with most of her career centered on clinical operations execution, develo

Innovating Patient Recruitment: A Conversation with BBK Worldwide Founders Joan F. Bachenheimer and Bonnie A. Brescia   The Conference Forum moderates a webcast featuring Joan F. Bachenheimer and Bonnie A. Brescia, the founders of BBK Worldwide, who walk us through the evolution of patient recruitment and engagement, the connection to the women’s and consumer healthcare movement, the need for changes in communication and the rise of the patient voice. They also address the impact of scientific advances on patient recruitment and the importance of preparing to meet the evolving changes. The timing of the webcast coincides with the company’s 40-year anniversary.   Guests:  Joan F. Bachenheimer, Founder, Chief Executive Officer, BBK Worldwide Bonnie A. Brescia, Founder, Chief Development Officer, BBK Worldwide   Moderated by: Valerie Bowling, Executive Director, Conference Forum   For more information on BBK Worldwide, visit www.bbkworldwide.com For more information on the Conference Forum, visit ww

Directors, Valerie Bowling and Kate Woda, discuss what to expect at the upcoming 10th annual Mobile Tech in Clinical Trials conference taking place on September 19, 2023 in Boston, MA.

Director, Valerie Bowling, reviews what to expect at the upcoming Clinical Research as a Care Option (CRAACO) conference taking place on May 22-23 at the Sheraton Imperial Hotel in Raleigh-Durham, NC.

In this podcast, you will hear a panel discussion moderated by Paul Jansen from the 2022 PODD Conference regarding the biggest challenges as well as future solutions to vaccine administration and distribution. Panelists include: Jeffrey T Blue, MerckDerek O’Hagan, PhD, GSK To learn more about the PODD Conference, please visit PODDConference.com.  

In this podcast, you will hear a panel discussion moderated by Mark DeStefano, Teva, from the 2022 PODD Conference regarding balancing the level of connected activity with user needs, determining how broadly or specifically to use connectivity and slowly implementing connectivity to provide good user acceptance. Panelists include: Kevin Deane, Phillips-Medisize, a Molex CompanyDavid Harrison, UCBLilly StairsBrad Womble, JabilAndrei Yosef, Eitan Medical To learn more about the PODD Conference, please visit PODDConference.com.  

  Why is enhancing the interferon pathway an attractive approach for treating cancer?What are the novel therapeutic approaches being investigated to harness the innate immune system to enhance the interferon pathway to treat cancer?What are the translational approaches being applied to better study therapeutics that activate the interferon pathway against hematologic and solid tumors and identify the patients who may respond better to these therapeutics? Christine Ward, PhD, Head, oncology Precision and Translational Medicine, Takeda Pharmaceuticals Learn more about the IO360° Summit at www.io360summit.com  

In this talk, first recorded at the 2022 IO360° Summit, Dr Rachel Haurwitz, CEO, Caribou Biosciences, addresses the big picture view of where the cell therapy field is going and how innovative CRISPR-based editing will help with the treatment of hematologic and solid tumors. Key topics include: Approach that requires highly specific and efficient multiplex genome editingWhat are some of the potential stumbling blocks?What are the tools for solving those challenges?Tackling solid tumors as the next frontier for cell therapies Rachel Haurwitz, PhD, President & CEO, Caribou Biosciences Learn more about the IO360° Summit at www.io360summit.com

Moderated by: Axel Hoos, MD, PhD, CEO, Scorpion Therapeutics Panelists: Jonathan Fassberg, Vice Chairman of Healthcare Investment Banking, OppenheimerIrina Margine, PhD, Principal, Biotech Private Equity, Wellington ManagementAsthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst, Truist SecuritiesGraig Suvannavejh, PhD, Managing Director, Equity Research Biopharmaceuticals & Biotechnology, Mizuho Securities USA Learn more about the IO360° Summit at www.io360summit.com

This panel, first recorded at the 2022 IO360° Summit addressed: What are the risks and implications of investing in cell/gene therapy companies who have no clinical data from programs available?Venture company perspectives on what they are investing in and why? • What science needs to be seen in order to invest in either a startup or IPO?What are investors/pharma partners looking for and how does that inform what people should be doing?How do we think about partnerships between organizations? Moderated by: Michael Polansky, CEO, Parker Group Panelists: Mark Bonyhadi, PhD, Senior Advisor, Qiming Venture PartnersElaine Cheung, SVP, Corporate Strategy & Business Development, Lyell ImmunopharmaArjun Goyal, MD, MPhil, MBA, Co-founder and Managing Director, Vida Ventures Learn more about the IO360° Summit at www.io360summit.com